

Rating: BUY | CMP: Rs953 | TP: Rs1,200

November 6, 2022

Q2FY23 Result Update

☑ Change in Estimates | ■ Target | ■ Reco

Change in Estimates

	Current		Previous	
	FY24E	FY25E	FY24E	FY25E
Rating	BUY		BUY	
Target Price	1,200		1,200	
Sales (Rs. m)	1,80,343	1,91,464	1,79,255	1,93,320
% Chng.	0.6	(1.0)		
EBITDA (Rs. m)	27,151	27,599	27,094	28,006
% Chng.	0.2	(1.5)		
EPS (Rs.)	65.7	66.5	66.2	68.3
% Chng.	(0.8)	(2.7)		

Key Financials - Consolidated

Y/e Mar	FY22	FY23E	FY24E	FY25E
Sales (Rs. m)	1,91,109	2,87,701	1,80,343	1,91,464
EBITDA (Rs. m)	21,499	26,588	27,151	27,599
Margin (%)	11.2	9.2	15.1	14.4
PAT (Rs. m)	15,285	18,695	19,285	19,506
EPS (Rs.)	52.1	63.7	65.7	66.5
Gr. (%)	15.0	22.4	3.2	1.1
DPS (Rs.)	12.0	14.0	16.0	17.0
Yield (%)	1.3	1.5	1.7	1.8
RoE (%)	26.6	26.4	22.6	19.5
RoCE (%)	34.4	34.8	29.1	25.0
EV/Sales (x)	1.4	0.9	1.4	1.3
EV/EBITDA (x)	12.2	9.8	9.3	8.8
PE (x)	18.3	15.0	14.5	14.3
P/BV (x)	4.4	3.6	3.0	2.6

Key Data

CROM.BO | CRIN IN

52-W High / Low	Rs.1,094 / Rs.709
Sensex / Nifty	60,950 / 18,117
Market Cap	Rs.280bn/ \$ 3,398m
Shares Outstanding	294m
3M Avg. Daily Value	Rs.540.59m

Shareholding Pattern (%)

Promoter's	57.45
Foreign	9.93
Domestic Institution	18.65
Public & Others	13.97
Promoter Pledge (Rs bn)	-

Stock Performance (%)

	1M	6M	12M
Absolute	(4.5)	5.1	22.1
Relative	(9.0)	(4.0)	20.4

Himanshu Binani

himanshubinani@plindia.com | 91-22-66322232

Superior margins drives outperformance..!!

Quick Pointers:

- EBITDA/tonne guidance to +Rs5500/tonne for FY23 as against their earlier guidance of Rs4000-4500/tonne
- Subsidy outstanding at Rs41.76bn as on 30th September'22 (up Rs24.7bn YoY, up Rs14.5bn QoQ)

Coromandel International (CRIN) reported revenue/EBITDA/PAT growth of 65%/42%/43% YoY respectively. Results were ahead of our and consensus estimates led by superior margins. Key highlights are 1) overall fertilizer sales volumes were up 12% YoY; 2) Crop protection posted flat YoY growth (+1% YoY); 3) derived EBITDA/tonne stood at +Rs6600 (1HFY23 +Rs6900 as against Rs5000/tonne in 1HFY22); 4) Market share (MS) stood flat at 19.2% in 2QFY23 (for 1HFY23 at 16.2% as against 18.4% in same period last year); 5) Phos. acid contracted for 3QFY23 at USD1175/tonne down 31% QoQ; 6) Subsidy outstanding at Rs41.76bn as on 30th September'22 (up Rs24.7bn YoY, up Rs14.5bn QoQ). Citing better margins for 1HFY23, management has revised upward their EBITDA/tonne guidance to +Rs5500/tonne for FY23 as against their earlier guidance of Rs4000-4500/tonne. However, softening of RM prices in turn would result into reduction in MRP/subsidy rates going forward in 2HFY23 in turn to weigh on the margins.

We anticipate CRIN to report stable margins over the longer term backed by a) efficient sourcing of RM's; b) benefits of backward integration; c) rising share of unique grades; d) product innovation and capacity expansion in both the business; e) enhanced focus on branding of products both in nutrition and CP segment. Factoring in 1HFY23 performance, we increase our FY23 EPS estimates by 6%, while we keep our FY24/25 EPS estimates largely unchanged. Maintain 'BUY' with unchanged TP of INR1200 based on 18x FY25E EPS.

- Margins continues to surprise positively:** Consolidated revenues stood at INR101.1bn up 65% YoY (PLe INR90bn) were largely driven by superior revenue growth in fertilizer business. Nutrient and other allied products revenues were up 73% YoY to INR94.6bn, while the crop protection reported a flat revenue growth (+1% YoY) to INR7.06bn. For 2QFY23, overall fertilizer sales volumes were up 12% YoY led by increase in marketing volumes (Non-urea traded volumes were down 24% YoY; while Urea traded volumes were up 83% YoY). Manufactured complex fertilizer volumes were up 19% YoY during 2QFY23. Derived manufactured EBITDA/tonne for 2QFY23 stands at Rs6600/tonne. Growth in CPC segment impacted by a) decline in exports revenue down 11% YoY in 2QFY23; b) Lower capacity utilization at all their plants at 53% in 2QFY23 as compared to 70-75% last year. Subsidy and non-subsidy business contribution in revenue and EBITDA stood at 89%/11% (2QFY22, 87%/13%) and 78%/22% (2QFY22, 71%/29%), respectively. Unique grade products contributed 32% of volume in 2QFY23 as against 45% in 2QFY22.

- **Reduction in NBS rates by Govt./price cuts is likely to exert pressure on margins in 2HFY23:** In line with the falling RM cost globally, the Govt. has revised downward their NBS subsidy payable for 2HFY23 (as compared to 1HFY23). However, we believe the reduction in subsidy is less than the fall in the RM prices (Phos. Acid prices down ~30% QoQ; while reduction in subsidy is ~2000/tonne for DAP). Hence going by the falling RM price trend, management alluded that there can be further reduction in subsidy/MRP going forward which in turn can exert pressure on the margins profile in 2HFY23. However, factoring in the 1HFY23 performance, CRIN remains confident of achieving fertilizer EBITDA/MT of +Rs5500 (as against the earlier guidance of Rs4000-4500/MT) in FY23E.
- **Crop protection segment impacted by lower exports demand:** CPC segment remained flat (+1% YoY) led by -11%/+7% YoY growth in exports/domestic business. Export market were impacted led by subdued demand for Mancozeb (contributing 45% of CPC revenues). While, capacity utilization across plants stood at 53% in 2QFY23 (as against 60-65% in 2QFY22). Going forward, management alluded for better demand of mancozeb in 2HFY23
- **New product launches coupled with enhanced focus on branding in Non subsidy business - to support growth:** Management envisaged that new product launches coupled with branding of their products both in the Nutrition and CP segment is likely to reap benefits in the medium term. The company continues with its endeavor to invest on R&D, expansion in distribution reach, and identifying newer off-patented molecules. CRIN has launched 4 new formulations (3 insecticides and 1 fungicides) in the CP segment in 1HFY23. ITI in the CPC business stood at ~25% in 1HFY22.

Conference Call highlights:

Fertiliser Business

- **Industry Sales Volumes :** up 10% YoY to 64.7 lakh tonnes v/s 58.4 lakh tonnes last year in 2QFY23. For 1HFY23, volumes stood at 119.19 lakh tonnes up 14% YoY vs 104.4 lakh tonnes.
- **CRIN sales volumes:** For 2QFY23, Phosphatic volumes (DAP + Complex) stood at 12.4lakh tonnes up 11% vs 11.2lakh tonnes last year; whereas manufactured phosphatic volumes were up 19% YoY to 11.06 lakh tonnes vs 9.27 lakh tonnes last year; however the trading volumes were down 30% YoY to 1.37 lakh tonnes vs 1.95 lakh tonnes last year.
- **Nutrient and allied business** contributed to 93%, while the crop protection business contributed 7% of the total revenues in 2QFY23. For 1HFY23, Nutrient and allied business contributed to 91%, while the crop protection business contributed 9% of the total revenues.
- **Subsidy/ Non-subsidy Revenue share:** stood at 89%/11% in 2QFY23 as against 87%/13% in the same period last year.
- **Subsidy/ Non-subsidy EBITDA share:** stood at 78%/22% in 2QFY23 as against as 71%/29% last year.

- **Subsidy Outstanding:** Subsidy outstanding stood at Rs41.76bn as on 30th September'22 as against Rs16.98bn in the same period last year.
- **Subsidy received** Rs38.66bn during the 2QFY23 as against Rs16.71bn last year. For 1HFY23 subsidy received stood at 40.02bn as against 21.62bn in the same period last year.; While for October'22 subsidy received Rs24bn.
- **Phosphoric acid prices** have been contracted at USD1175/tonne for 3QFY23 as against USD1715/tonnes for 2QFY23.
- **Market share in phosphatic** remained same as last year at 19.2% in 2QFY23. For 1HFY23 stood at 16.2% v/s 18.4% in same period last year.
- **SSP sales volumes** were 0.24mn mt up 8% YoY in 2QFY23
- **SSP market share** declined to 14.3% from 16.1% last year.
- **Production and capacity utilization** in fertiliser segment: Capacity utilization at 107% for complex fertilisers in 2QFY23 and operated at 99% during 1HFY23.
- **CRIN's EBITDA/tonne** should increase realigning their 1HFY23 numbers; Company has now revised their EBITDA/tonne guidance for FY23 at +Rs5500/tonne (v/s their original guidance of Rs4000-4500/tonne).

Crop Protection business

- **Production and capacity utilization in CPC segment:** Capacity utilization at 53% as against 77% in the same period last year.
- Muted performance in the CPC segment: was largely driven by 1) excessive rains leading to lower liquidation; 2) downsizing on the lower margin products resulting in reduction in volumes; 3) pressure on mancozeb both in the export market and domestic market.
- Margins in CPC business were under pressure led by higher RM cost scenario and inability to fully pass on the inflated cost. Going forward, margins are expected to improve.
- Contribution of Mancozeb stood at 45% of the overall CPC revenues as against 60-65% in the same period last year.

Exhibit 1: SOTP Valuation – FY25E

SOTP Valuation (Rs Mn)	EBITDA	Assigned EV (x)	EV	Per Share
Subsidy business	19,465	11x	2,12,174	723
Crop protection business	6,218	14x	87,049	297
Other business	2,116	8x	16,926	58
Total	27,799	11x	3,16,149	1,078
Net Debt			(35,768)	(122)
Market Cap.			3,51,917	
Value/Share			1200	1,200
CMP			953	
Potential Upside			25.9%	
Implied PE			18.1	
Implied EV/EBITDA			11.4	

Source: PL

Exhibit 2: Q2FY23 Result Overview (Rs mn)

Year to March	Q2FY23	Q2FY22	YoY gr. (%)	Q1FY23	QoQ gr. (%)	1HFY23	1HFY22	YoY gr. (%)
Revenues	1,01,134	61,475	64.5	57,291	76.5	1,58,425	98,114	61.5
Raw material	82,288	46,954	75.3	43,145	90.7	1,25,433	72,340	73.4
Staff costs	1,699	1,352	25.7	1,560	8.9	3,260	2,790	16.9
Other expenditure	6,577	5,738	14.6	5,732	14.7	12,309	10,722	14.8
Total expenditure	90,564	54,043	67.6	50,437	79.6	1,41,001	85,851	64.2
EBITDA	10,570	7,432	42.2	6,854	54.2	17,424	12,263	42.1
Depreciation	457	421	8.6	446	2.6	903	844	7.0
EBIT	10,112	7,011	44.2	6,408	57.8	16,521	11,419	44.7
Interest	542	192	182.7	266	104.1	808	363	122.7
Other income	311	189	64.9	536	(41.9)	847	406	108.5
Profit Before Tax	9,881	7,008	41.0	6,678	48.0	16,560	11,463	44.5
Less: Provision for Tax	2,481	1,819	36.4	1,703	45.7	4,184	2,923	43.1
PAT	7,400	5,189	42.6	4,975	48.7	12,376	8,539	44.9
Minority interest	-	-	NA	-	NA	-	-	NA
Add: Share of profit from associates	6	4	30.2	15	NA	21	32	(33.9)
Adjusted Profit	7,406	5,193	42.6	4,991	48.4	12,396	8,571	44.6
Add: Exceptional items (net of tax)	-	-	-	-	-	-	-	-
Reported Profit	7,406	5,193	42.6	4,991	48.4	12,396	8,571	44.6
No. of Diluted shares (mn)	293	293		293		293	293	
Adjusted Diluted EPS	25.3	17.8	42.6	17.1	48.4	42.4	29.3	44.6
As % of net revenues								
Raw material	81.4	76.4		75.3		79.2	73.7	
Staff expenses	1.7	2.2		2.7		2.1	2.8	
Other expenditure	6.5	9.3		10.0		7.8	10.9	
EBITDA	10.5	12.1		12.0		11.0	12.5	
Net profit	7.3	8.4		8.7		7.8	8.7	

Source: Company, PL

Exhibit 3: Quarterly Sales volumes


Sales volume (MT)	Q2FY23	Q2FY22	YoY gr. (%)	Q1FY23	QoQ gr. (%)	1HFY23	1HFY22	YoY gr. (%)
Non Urea - Manufactured	11,06,000	9,27,000	19.3	6,88,000	60.8	17,94,000	16,94,000	5.9
SSP-Manufactured	2,43,000	2,26,000	7.5	1,59,000	52.8	4,02,000	4,12,000	(2.4)
Non Urea - Traded	1,57,000	2,06,000	(23.8)	43,000	265.1	2,00,000	2,31,000	(13.4)
Urea - Traded	3,71,000	2,03,000	82.8	1,64,000	126.2	5,35,000	2,51,000	113.1
Total Traded	5,28,000	4,09,000	29.1	2,07,000	155.1	7,35,000	4,82,000	52.5
Total	18,77,000	15,62,000	20.2	10,54,000	78.1	29,31,000	25,88,000	13.3

Source: Company, PL

Exhibit 4: Segmental revenue break-up


	2QFY20	3QFY20	4QFY20	1QFY21	2QFY21	3QFY21	4QFY21	1QFY22	2QFY22	3QFY22	4QFY22	1QFY23	2QFY23
Segment Revenue (Gross)													
- Nutrient and other allied products	43,914	28,408	24,362	28,072	40,142	30,453	23,652	30,705	54,784	44,836	36,828	51,105	94,612
- Crop Protection	5,099	4,625	4,420	4,202	6,371	5,114	5,152	6,315	7,015	6,216	5,561	6,607	7,068
Less: Intersegment revenue	433	247	89	142	400	236	245	380	323	316	120	422	547
Income from Operations	48,580	32,787	28,693	32,132	46,113	35,330	28,560	36,639	61,475	50,736	42,268	57,291	1,01,134
Segment Results (EBIT)													
- Nutrient and other allied products	6,282	3,649	3,119	3,695	7,064	4,087	2,006	3,987	6,121	4,382	3,248	6,022	9,553
- Crop Protection	834	713	598	542	1,385	894	646	823	1,198	928	735	867	1,053
Less: Unallocated expenses	(403)	(451)	(260)	(534)	(438)	(412)	(509)	(402)	(307)	(291)	(640)	(481)	(493)
Less: Finance Cost	(664)	(459)	(434)	(434)	(253)	(205)	(164)	(171)	(192)	(178)	(214)	(266)	(542)
Add: Other Income	95	91	115	107	82	89	158	218	189	259	768	536	311
Less: Exceptional item	-	-	-	-	-	-	-	-	-	-	-	-	-
Profit before Tax	6,145	3,544	3,137	3,376	7,841	4,453	2,136	4,455	7,008	5,101	3,897	6,678	9,881

Source: Company, PL

Exhibit 5: Revenue growth a function of higher subsidy



Source: Company, PL

Exhibit 6: EBITDA and margins trend (%)



Source: Company, PL

Exhibit 7: EBITDA/tonne continues to surprise positively



Source: Company, PL

Financials

Income Statement (Rs m)

Y/e Mar	FY22	FY23E	FY24E	FY25E
Net Revenues	1,91,109	2,87,701	1,80,343	1,91,464
YoY gr. (%)	34.5	50.5	(37.3)	6.2
Cost of Goods Sold	1,42,165	2,29,754	1,21,451	1,31,124
Gross Profit	48,943	57,948	58,891	60,339
Margin (%)	25.6	20.1	32.7	31.5
Employee Cost	5,872	6,329	7,214	7,084
Other Expenses	21,573	25,030	24,527	25,656
EBITDA	21,499	26,588	27,151	27,599
YoY gr. (%)	6.7	23.7	2.1	1.7
Margin (%)	11.2	9.2	15.1	14.4
Depreciation and Amortization	1,727	1,941	2,298	2,620
EBIT	19,772	24,647	24,853	24,979
Margin (%)	10.3	8.6	13.8	13.0
Net Interest	755	1,245	747	672
Other Income	1,443	1,861	1,954	2,052
Profit Before Tax	20,460	25,263	26,061	26,359
Margin (%)	10.7	8.8	14.5	13.8
Total Tax	5,213	6,568	6,776	6,853
Effective tax rate (%)	25.5	26.0	26.0	26.0
Profit after tax	15,247	18,695	19,285	19,506
Minority interest	-	-	-	-
Share Profit from Associate	37	-	-	-
Adjusted PAT	15,285	18,695	19,285	19,506
YoY gr. (%)	15.0	22.3	3.2	1.1
Margin (%)	8.0	6.5	10.7	10.2
Extra Ord. Income / (Exp)	-	-	-	-
Reported PAT	15,285	18,695	19,285	19,506
YoY gr. (%)	15.0	22.3	3.2	1.1
Margin (%)	8.0	6.5	10.7	10.2
Other Comprehensive Income	-	-	-	-
Total Comprehensive Income	15,285	18,695	19,285	19,506
Equity Shares O/s (m)	294	293	293	293
EPS (Rs)	52.1	63.7	65.7	66.5

Source: Company Data, PL Research

Balance Sheet Abstract (Rs m)

Y/e Mar	FY22	FY23E	FY24E	FY25E
Non-Current Assets				
Gross Block	38,338	46,943	53,943	60,943
Tangibles	38,051	46,452	53,452	60,452
Intangibles	288	491	491	491
Acc: Dep / Amortization	17,212	19,153	21,451	24,071
Tangibles	17,212	19,153	21,451	24,071
Intangibles	-	-	-	-
Net fixed assets	21,126	27,790	32,492	36,872
Tangibles	20,839	27,299	32,001	36,381
Intangibles	288	491	491	491
Capital Work In Progress	1,198	1,198	1,198	1,198
Goodwill	3	-	-	-
Non-Current Investments	2,435	2,435	2,435	2,435
Net Deferred tax assets	(660)	(638)	(638)	(638)
Other Non-Current Assets	-	-	-	-
Current Assets				
Investments	-	-	-	-
Inventories	36,632	50,357	36,602	39,517
Trade receivables	2,649	4,602	5,718	6,938
Cash & Bank Balance	17,533	20,051	27,861	35,768
Other Current Assets	12,930	12,854	12,854	12,854
Total Assets	1,12,847	1,38,545	1,39,380	1,56,813
Equity				
Equity Share Capital	294	293	293	293
Other Equity	63,289	77,877	92,467	1,06,985
Total Networth	63,583	78,170	92,760	1,07,278
Non-Current Liabilities				
Long Term borrowings	-	-	-	-
Provisions	9,469	9,380	9,380	9,380
Other non current liabilities	-	-	-	-
Current Liabilities				
ST Debt / Current of LT Debt	0	-	-	-
Trade payables	39,135	50,357	36,602	39,517
Other current liabilities	-	-	-	-
Total Equity & Liabilities	1,12,847	1,38,545	1,39,380	1,56,813

Source: Company Data, PL Research

Cash Flow (Rs m)

Y/e Mar	FY22	FY23E	FY24E	FY25E
PBT	20,498	25,263	26,061	26,359
Add. Depreciation	1,727	1,941	2,298	2,620
Add. Interest	755	1,245	747	672
Less Financial Other Income	1,443	1,861	1,954	2,052
Add. Other	(1,081)	(1,861)	(1,954)	(2,052)
Op. profit before WC changes	21,898	26,588	27,151	27,599
Net Changes-WC	3,716	(5,386)	(2,079)	(2,231)
Direct tax	(4,834)	(6,546)	(6,776)	(6,853)
Net cash from Op. activities	20,781	14,655	18,296	18,515
Capital expenditures	(2,766)	(8,601)	(7,000)	(7,000)
Interest / Dividend Income	1,053	1,861	1,954	2,052
Others	(14,507)	1,174	-	-
Net Cash from Invt. activities	(16,220)	(5,566)	(5,046)	(4,948)
Issue of share cap. / premium	43	-	-	-
Debt changes	(16)	0	-	-
Dividend paid	(3,521)	(4,108)	(4,694)	(4,988)
Interest paid	(342)	(1,245)	(747)	(672)
Others	(589)	-	-	-
Net cash from Fin. activities	(4,425)	(5,353)	(5,441)	(5,660)
Net change in cash	135	3,736	7,810	7,907
Free Cash Flow	18,001	6,054	11,296	11,515

Source: Company Data, PL Research

Key Financial Metrics

Y/e Mar	FY22	FY23E	FY24E	FY25E
Per Share(Rs)				
EPS	52.1	63.7	65.7	66.5
CEPS	58.0	70.3	73.6	75.4
BVPS	216.6	266.4	316.2	365.6
FCF	61.3	20.6	38.5	39.2
DPS	12.0	14.0	16.0	17.0
Return Ratio(%)				
RoCE	34.4	34.8	29.1	25.0
ROIC	36.8	35.9	31.9	28.8
RoE	26.6	26.4	22.6	19.5
Balance Sheet				
Net Debt : Equity (x)	(0.3)	(0.3)	(0.3)	(0.3)
Net Working Capital (Days)	0	6	12	13
Valuation(x)				
PER	18.3	15.0	14.5	14.3
P/B	4.4	3.6	3.0	2.6
P/CEPS	16.4	13.6	13.0	12.6
EV/EBITDA	12.2	9.8	9.3	8.8
EV/Sales	1.4	0.9	1.4	1.3
Dividend Yield (%)	1.3	1.5	1.7	1.8

Source: Company Data, PL Research

Quarterly Financials (Rs m)

Y/e Mar	Q3FY22	Q4FY22	Q1FY23	Q2FY23
Net Revenue	50,736	42,268	57,291	1,01,134
YoY gr. (%)	43.6	48.0	56.4	64.5
Raw Material Expenses	38,408	31,417	43,145	82,288
Gross Profit	12,328	10,851	14,146	18,846
Margin (%)	24.3	25.7	24.7	18.6
EBITDA	5,449	3,797	6,854	10,570
YoY gr. (%)	108.8	(21.4)	(7.8)	94.0
Margin (%)	10.7	9.0	12.0	10.5
Depreciation / Depletion	429	454	446	457
EBIT	5,020	3,343	6,408	10,112
Margin (%)	9.9	7.9	11.2	10.0
Net Interest	178	214	266	542
Other Income	259	768	536	311
Profit before Tax	5,101	3,897	6,678	9,881
Margin (%)	10.1	9.2	11.7	9.8
Total Tax	1,298	992	1,703	2,481
Effective tax rate (%)	25.4	25.4	25.5	25.1
Profit after Tax	3,803	2,905	4,976	7,400
Minority interest	-	-	-	-
Share Profit from Associates	13	(7)	15	6
Adjusted PAT	3,803	2,905	4,976	7,400
YoY gr. (%)	14.5	86.1	48.5	42.6
Margin (%)	7.5	6.9	8.7	7.3
Extra Ord. Income / (Exp)	-	-	-	-
Reported PAT	3,816	2,898	4,991	7,406
YoY gr. (%)	14.3	85.9	47.8	42.6
Margin (%)	7.5	6.9	8.7	7.3
Other Comprehensive Income	-	-	-	-
Total Comprehensive Income	3,816	2,898	4,991	7,406
Avg. Shares O/s (m)	293	293	293	293
EPS (Rs)	13.0	9.9	17.0	25.3

Source: Company Data, PL Research

Price Chart
Recommendation History


No.	Date	Rating	TP (Rs.)	Share Price (Rs.)
1	12-Oct-22	BUY	1,200	973
2	27-Dec-21	BUY	960	745

Analyst Coverage Universe

Sr. No.	Company Name	Rating	TP (Rs)	Share Price (Rs)
1	Bayer Cropscience	Accumulate	5,650	4,803
2	Chambal Fertilizers & Chemicals	BUY	480	320
3	Coromandel International	BUY	1,200	973
4	Dhanuka Agritech	BUY	940	728
5	Godrej Agrovet	Accumulate	570	520
6	Insecticides India	Hold	920	701
7	P.I. Industries	BUY	3,450	2,956
8	Rallis India	BUY	250	226
9	Sharda Cropchem	BUY	660	446
10	Sumitomo Chemical India	BUY	610	493
11	UPL	BUY	1,070	717

PL's Recommendation Nomenclature (Absolute Performance)

Buy	: > 15%
Accumulate	: 5% to 15%
Hold	: +5% to -5%
Reduce	: -5% to -15%
Sell	: < -15%
Not Rated (NR)	: No specific call on the stock
Under Review (UR)	: Rating likely to change shortly



ANALYST CERTIFICATION

(Indian Clients)

We/I, Mr. Himanshu Binani- MBA Finance Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

(US Clients)

The research analysts, with respect to each issuer and its securities covered by them in this research report, certify that: All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and No part of his or her or their compensation was, is or will be directly related to the specific recommendation or views expressed in this research report.

DISCLAIMER

Indian Clients

Prabhudas Lilladher Pvt. Ltd, Mumbai, India (hereinafter referred to as "PL") is engaged in the business of Stock Broking, Portfolio Manager, Depository Participant and distribution for third party financial products. PL is a subsidiary of Prabhudas Lilladher Advisory Services Pvt Ltd. which has its various subsidiaries engaged in business of commodity broking, investment banking, financial services (margin funding) and distribution of third party financial/other products, details in respect of which are available at www.plindia.com.

This document has been prepared by the Research Division of PL and is meant for use by the recipient only as information and is not for circulation. This document is not to be reported or copied or made available to others without prior permission of PL. It should not be considered or taken as an offer to sell or a solicitation to buy or sell any security.

The information contained in this report has been obtained from sources that are considered to be reliable. However, PL has not independently verified the accuracy or completeness of the same. Neither PL nor any of its affiliates, its directors or its employees accepts any responsibility of whatsoever nature for the information, statements and opinion given, made available or expressed herein or for any omission therein.

Recipients of this report should be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The suitability or otherwise of any investments will depend upon the recipient's particular circumstances and, in case of doubt, advice should be sought from an independent expert/advisor.

Either PL or its affiliates or its directors or its employees or its representatives or its clients or their relatives may have position(s), make market, act as principal or engage in transactions of securities of companies referred to in this report and they may have used the research material prior to publication.

PL may from time to time solicit or perform investment banking or other services for any company mentioned in this document.

PL is in the process of applying for certificate of registration as Research Analyst under Securities and Exchange Board of India (Research Analysts) Regulations, 2014

PL submits that no material disciplinary action has been taken on us by any Regulatory Authority impacting Equity Research Analysis activities.

PL or its research analysts or its associates or his relatives do not have any financial interest in the subject company.

PL or its research analysts or its associates or his relatives do not have actual/beneficial ownership of one per cent or more securities of the subject company at the end of the month immediately preceding the date of publication of the research report.

PL or its research analysts or its associates or his relatives do not have any material conflict of interest at the time of publication of the research report.

PL or its associates might have received compensation from the subject company in the past twelve months.

PL or its associates might have managed or co-managed public offering of securities for the subject company in the past twelve months or mandated by the subject company for any other assignment in the past twelve months.

PL or its associates might have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months.

PL or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months

PL or its associates might have received any compensation or other benefits from the subject company or third party in connection with the research report.

PL encourages independence in research report preparation and strives to minimize conflict in preparation of research report. PL or its analysts did not receive any compensation or other benefits from the subject Company or third party in connection with the preparation of the research report. PL or its Research Analysts do not have any material conflict of interest at the time of publication of this report.

It is confirmed that Mr. Himanshu Binani- MBA Finance Research Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

The Research analysts for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

The research analysts for this report has not served as an officer, director or employee of the subject company PL or its research analysts have not engaged in market making activity for the subject company

Our sales people, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest.

PL and its associates, their directors and employees may (a) from time to time, have a long or short position in, and buy or sell the securities of the subject company or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company or act as an advisor or lender/borrower to the subject company or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

US Clients

This research report is a product of Prabhudas Lilladher Pvt. Ltd., which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by Prabhudas Lilladher Pvt. Ltd. only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, Prabhudas Lilladher Pvt. Ltd. has entered into an agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo").

Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

Prabhudas Lilladher Pvt. Ltd.

3rd Floor, Sadhana House, 570, P. B. Marg, Worli, Mumbai-400 018, India | Tel: (91 22) 6632 2222 Fax: (91 22) 6632 2209

www.plindia.com